The Role of Corticosteroids in Treatment Sequencing

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.

Tweet

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses sequencing treatment in patients with metastatic castration resistant prostate cancer.

The administration of corticosteroids has many positive and negative effects in the long-term for patients with prostate cancer. The use of these agents should be personalized based on individual factors, such as diabetes. This utilization could also be utilized to help determine appropriate sequences.

Clinical Pearls

Several new agents have been recently approved, each with a very unique mechanism of action. At this point, there is not a clear strategy for sequencing these agent but opportunities exist for personalization, such as not using corticosteroids in diabetic patients.

  • The individualization of corticosteroid administration could be utilized in treatment sequencing
  • Several new agents have been recently approved, each with a very unique mechanism of action with very little data on sequencing
  • Currently, Oh notes, there is not data suggesting a single optimal approach but corticosteroid eligibility could help guide treatment